Daftar Kandidat Vaksin COVID-19 yang Sedang di Uji Klinik di Seluruh Dunia
foto istimewa
Majalah Farmasetika – Pengembangan vaksin untuk COVID-19 sedang berlangsung, dengan banyak kandidat vaksin sedang dipelajari dalam uji klinis. Apoteker adalah penyedia perawatan kesehatan di garis depan dalam respons negara terhadap COVID-19. Asosiasi Apoteker Amerika (American Pharmacists Association) merilis 11 daftar kandidat vaksin COVID-19 hingga 13 April 2020.
Di negara maju termasuk Amerika Serikat, Apoteker dapat memainkan peran kunci dalam memberikan imunisasi terhadap virus SARS-CoV-2, ketika vaksin tersedia. Berikut adalah daftarnya :
Safety and Immunogenicity Study of 2019-nCoVVaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19)
COVID-19
Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of placebo at the emergency vaccination schedule
(and 3 more…)
Safety indexes of adverse reactions
Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14）
Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)
(and 7 more…)
744
Suining County Center for Disease Control and Prevention
Xuzhou, Jiangsu, China
6
Not yet recruiting NEW
Measles Vaccine in HCW
Covid19
Drug: Measles-Mumps-Rubella Vaccine
COVID-19 disease incidence
SARS-CoV-2 pneumonia
Critical care admission duration with SARS-CoV-2
Oxygen therapy with SARS-CoV-2
200
Cairo University Hospital
Cairo, Egypt
7
Not yet recruiting NEW
Performance Evaluation of BCG vs COVID-19
COVID-19
Biological: vaccine BCG
Other: Placebo
Primary outcome
Secondary outcome
1000
Program for Research and Control in Tropical Diseases – PECET
Medellín, Antioquia, Colombia
8
Recruiting NEW
BCG Vaccination to Protect Healthcare Workers Against COVID-19
Coronavirus Disease 2019 (COVID-19)
Febrile Respiratory Illness
Corona Virus Infection
COVID-19
Drug: BCG Vaccine
COVID-19 disease incidence
Severe COVID-19 disease incidence
COVID-19 incidence by 12 months
(and 29 more…)
4170
Epworth Victoria Parade
Melbourne, Victoria, Australia
Royal Children’s Hospital
Melbourne, Victoria, Australia
Epworth Richmond
Melbourne, Victoria, Australia
(and 5 more…)
9
Active, not recruiting
Phase I Clinical Trial of a COVID-19Vaccine in 18-60 Healthy Adults
COVID-19
Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Safety indexes of adverse reactions
Safety indexes of adverse events
Safety indexes of SAE
(and 10 more…)
108
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
10
Active, not recruiting NEW
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
COVID-19
Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
Other: Placebo
Occurrence of adverse reactions
Anti SARS-CoV-2 S antibody response(ELISA)
Neutralizing antibody response to SARS-CoV-2
(and 3 more…)
500
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
11
Not yet recruiting NEW
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
COVID-19
Biological: bacTRL-Spike
Other: Placebo
Frequency of Adverse Events
SARS-CoV-2 antibodies
Incidence of COVID-19 infection
(and 3 more…)
84
Vaccine Evaluation Center, BC Children’s Hospital Research Institute, University of British Columbia.
Vancouver, British Columbia, Canada
Canadian Center for Vaccinology Dalhousie University, IWK Health Centre
Halifax, Nova Scotia, Canada
12
Recruiting NEW
COVID-19 and Vaccination Attitudes
COVID-19
Other: Survey
How vaccination and other attitudes are affected by COVID
1000
Survey
London, United Kingdom
13
Recruiting NEW
A Study of a Candidate COVID-19Vaccine (COV001)
Coronavirus
Biological: ChAdOx1 nCoV-19
Biological: MenACWY
Biological: ChAdOx1 nCoV-19 boost
Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases
Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)
Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms
(and 8 more…)
1112
NIHR WTCRF, University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
St Georges University Hospital NHS Foundation Trust
London, Tooting, United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, United Kingdom
(and 3 more…)
14
Recruiting NEW
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.
SARS-CoV 2
Immunization; Infection
Status of Immunization
400
Medical University of Vienna, Division for Nephrology and Dialysis
Vienna, Austria
15
Not yet recruiting NEW
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020
Covid-19
Other: convalescent plasma
Change in COVID-19 severity status
2000
Hilton Pharma Pvt. Ltd.
Karachi, Sindh, Pakistan
16
Recruiting NEW
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
COVID-19
BCG Vaccination
Diagnostic Test: Tuberculin test
Pneumonia severity index
Need for ICU admission
COVID -19 test conversion
Mortality
100
AssiutU
Assiut, Egypt
17
Not yet recruiting NEW
BCG Vaccine for Health Care Workers as Defense Against SARS-COV2
Coronavirus
Coronavirus Infection
Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
Coronavirus as the Cause of Diseases Classified Elsewhere
Biological: BCG Vaccine
Biological: Placebo Vaccine
incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo
COVID19-related disease severity (measured by ordinal severity scale) following BCG vaccination compared to placebo
700
Harvard T.H. Chan School of Public Health
Boston, Massachusetts, United States
Texas A&M University
Bryan, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
(and 3 more…)
18
Recruiting
Safety and Immunogenicity Study of 2019-nCoVVaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)
Corona Virus Infection
Immunisations
Biological: mRNA-1273
Frequency of solicited local reactogenicity adverse events (AEs)
Frequency of any medically-attended adverse events (MAAEs)
Frequency of any new-onset chronic medical conditions (NOCMCs)
(and 9 more…)
45
Emory Vaccine Center – The Hope Clinic
Decatur, Georgia, United States
National Institutes of Health – Clinical Center – Vaccine Research Center Clinical Trials Program
Bethesda, Maryland, United States
Kaiser Permanente Washington Health Research Institute – Vaccines and Infectious Diseases
Seattle, Washington, United States
Farmasetika.com (ISSN : 2528-0031) merupakan situs yang berisi informasi farmasi terkini berbasis ilmiah dan praktis dalam bentuk Majalah Farmasetika. Di situs ini merupakan edisi majalah populer. Sign Up untuk bergabung di komunitas farmasetika.com.
Download aplikasi Android Majalah Farmasetika, Caping, atau Baca di smartphone, Ikuti twitter, instagram dan facebook kami.
Terimakasih telah ikut bersama memajukan bidang farmasi di Indonesia.